

Product Name: ABT-263 (Navitoclax)

Revision Date: 10/26/2023

Product Data Sheet

ABT-263 (Navitoclax)

Cat. No.: A3007

CAS No.: 923564-51-6

Formula: C47H55CIF3N5O6S3

M.Wt: 974.61

Synonyms: Navitoclax,ABT-263,ABT263,ABT 263

Target: Apoptosis

Pathway: Bcl-2 Family

Storage: Desiccate at -20°C

Solvent & Solubility

≥48.73 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	1.0261 mL	5.1303 mL	10.2605 mL
	5 mM	0.2052 mL	1.0261 mL	2.0521 mL
	10 mM	0.1026 mL	0.5 <mark>1</mark> 30 mL	1.0261 mL

Please refer to the solubility information to select the appropriate solvent

Biological Activity

Shortsummary	Potent Bcl-2 family inhibitor,	inhibits Bcl-2, Bcl-xL, and Bcl-w	
IC ₅₀ & Target	≤ 0.5 nM (Ki) (Bcl-xL), ≤1 nM (Ki) (Bcl-2), ≤ 1 nM (Ki) (Bcl-w)		
	Cell Viability Assay		
	Cell Line:	Murine DO11.10 T-hybridoma cells expressing murine Bcl-2, Bcl-xL and Bcl-w proteins	
In Vitro	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or	
		shake it in the ultrasonic bath for a while.Stock solution can be stored below	
		-20°C for several months.	

	Reacting conditions:	Reacting conditions: None specifc suggestion			
	Applications:	ABT-263 is an antitumor effector in preclinical and early clinical studies. It binds			
		to Bcl-2, Bcl-xL, and Bcl-w in vitro, but only targets Bcl-2 in vivo. In human			
		non-Hodgkin lymphomas, high expression of Bcl-2 sensitized to ABT-263			
	B Junton	elevated proapoptotic Bim.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	Immune-deficient NOD/SCID or NOD/SCID, ILγ receptor negative mice			
	Dosage form:	Orally taken at 100 mg/kg/day for 21 days			
	Applications:	ABT-263 can largely inhibited the activity of patient-derived pediatric acute			
		lymphoblastic leukemia xenograft. ABT-263 sensitivity was correlated with low			
		MCL1 mRNA expression levels. BH3 profiling revealed that resistance to			
		ABT-263 correlated with mitochondrial priming by NOXA peptide.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	30	slightly differ with the theoretical value. This is caused by an experimental			
	to the Unitrovin	system error and it is normal.			

Product Citations

- 1. Santos LC, Vogel R, et al. "Mitochondrial origins of fractional control in regulated cell death." Nat Commun. 2019 Mar 21;10(1):1313.PMID:30899020
- 2. Joe T Sharick, Christine M Walsh, et al. "Optical Metabolic Imaging of Heterogeneous Drug Response in Pancreatic Cancer Patient Organoids." bioRxiv. 2019 February 06.
- 3. Wu S, Fatkhutdinov N, et al. "SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells." Nat Commun.

2018 Oct 8;9(1):4116.PMID:30297712

4. Bera R, Chiu MC, et al. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of

PRDX2 in Myeloid Leukemia Cells." Neoplasia. 2018 Nov;20(11):1106-1120.PMID:30245403

5. Roscoe I, Parker M, et al. "Human Serum Albumin and the p53-Derived Peptide Fusion Protein Promotes Cytotoxicity Irrespective of p53 Status in Cancer Cells." Mol Pharm. 2018 Oct 10.PMID:30226785

See more customer validations on www.apexbt.com.

References

- 1. Mérino D1, Khaw SL, Glaser SP et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells Blood. 2012 Jun 14;119(24):5807-16.
- 2. Suryani S, Carol H, Chonghaile TN et al. Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. Clin Cancer Res. 2014 Jul 10.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



ARELEGIA E DO UN TURBON



A Reference to detection to deposit the contraction